Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.

Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW.

BJU Int. 2012 May;109(10):1495-502. doi: 10.1111/j.1464-410X.2011.10555.x. Epub 2011 Sep 20.

2.

Androgen deprivation therapy: evidence-based management of side effects.

Ahmadi H, Daneshmand S.

BJU Int. 2013 Apr;111(4):543-8. doi: 10.1111/j.1464-410X.2012.11774.x. Epub 2013 Jan 25. Review.

3.

Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.

Harrington JM, Schwenke DC, Epstein DR, Bailey DE Jr.

Oncol Nurs Forum. 2014 Jan 1;41(1):21-9. doi: 10.1188/14.ONF.21-29.

4.

Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.

Shahani S, Braga-Basaria M, Basaria S.

J Clin Endocrinol Metab. 2008 Jun;93(6):2042-9. doi: 10.1210/jc.2007-2595. Epub 2008 Mar 18. Review.

PMID:
18349064
5.

Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.

Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

BJU Int. 2012 Aug;110(4):492-8. doi: 10.1111/j.1464-410X.2011.10754.x. Epub 2011 Nov 17.

6.

An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.

Zhu W, Xu H, Ma J, Guo J, Xue W, Gu B, Sheng L, Yao X, Sun F, Gong J, Qiu W, Ding Q, Jiang H.

Urol Int. 2017;98(1):79-84. doi: 10.1159/000448691. Epub 2016 Sep 30.

PMID:
27684440
7.

Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.

Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS.

Cancer. 2006 Feb 1;106(3):581-8.

8.

Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.

Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ.

Pharmacotherapy. 2008 Dec;28(12):1511-22. doi: 10.1592/phco.28.12.1511. Review.

PMID:
19025432
9.
10.

Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial.

Bourke L, Gilbert S, Hooper R, Steed LA, Joshi M, Catto JW, Saxton JM, Rosario DJ.

Eur Urol. 2014 May;65(5):865-72. doi: 10.1016/j.eururo.2013.09.040. Epub 2013 Oct 4.

PMID:
24119318
11.

Metformin in prostate cancer: two for the price of one.

Clements A, Gao B, Yeap SH, Wong MK, Ali SS, Gurney H.

Ann Oncol. 2011 Dec;22(12):2556-60. doi: 10.1093/annonc/mdr037. Epub 2011 Mar 18. Review.

PMID:
21421541
12.

Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.

Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL.

BJU Int. 2013 May;111(5):745-52. doi: 10.1111/j.1464-410X.2012.11758.x. Epub 2013 Jan 17.

13.

Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.

Harden KA, Cowan PA, Velasquez-Mieyer P, Patton SB.

J Am Acad Nurse Pract. 2007 Jul;19(7):368-77.

PMID:
17680902
14.

Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.

Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM; TAP22 Investigators Group..

BJU Int. 2012 Nov;110(9):1262-9. doi: 10.1111/j.1464-410X.2012.11120.x. Epub 2012 Apr 13.

15.

Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.

Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD.

Med J Aust. 2011 Mar 21;194(6):301-6. Review.

PMID:
21426285
16.

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.

Lee CE, Leslie WD, Lau YK.

BMC Cancer. 2012 Mar 21;12:103. doi: 10.1186/1471-2407-12-103.

17.

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.

Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM.

J Clin Endocrinol Metab. 2005 Dec;90(12):6410-7. Epub 2005 Sep 27.

PMID:
16189261
18.

Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer.

Gilbert SE, Tew GA, Fairhurst C, Bourke L, Saxton JM, Winter EM, Rosario DJ.

Br J Cancer. 2016 Feb 16;114(4):401-8. doi: 10.1038/bjc.2015.479. Epub 2016 Jan 14.

19.

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group..

Ann Intern Med. 2005 Apr 19;142(8):611-9.

20.

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S.

J Clin Oncol. 2006 Aug 20;24(24):3979-83.

PMID:
16921050

Supplemental Content

Support Center